Grön, a Portland, Ore.-based producer of cannabis-infused edibles, has built its business with a focus on minor cannabinoids and effects-based products, including its popular CBN offerings.
But its product mix may soon have to change.
Regulators in Oregon, concerned about the potential of harmful byproducts in artificially derived cannabinoids—and particularly worried about the unregulated delta-8 products that were appearing on the shelves of grocery stores and gas stations across the state—banned the sale of all synthetic cannabinoids on the open market as of July 1, 2022.
Products containing artificially derived cannabinoids may still be sold by cannabis retailers licensed through the Oregon Liquor and Cannabis Commission (OLCC) until July 1, 2023, at which point the products must be approved by the U.S. Food and Drug Administration (FDA) in order to remain on dispensary shelves.
Christine Smith, Grön’s founder and CEO, says that while the OLCC is likely trying to protect consumers, regulators are actually stifling innovation and hindering Oregon’s cannabis industry from achieving its full potential.
CBN products comprise nearly 30% of Grön’s sales, Smith says, and she and her team are uncertain about the products’ future in Oregon. The company plans for production and packaging up to six months in advance and could